Helus Pharma Q1 FY2027: $47.8M Net Loss, $166.4M Cash, Phase 3 Data on Track for Q4
HELP has more than doubled off its 52-week low of $3.76.
Summary
Helus Pharma reported a $47.8M quarterly net loss with $166.4M in cash, while confirming Phase 3 APPROACH data remains on track for Q4 2026. Subsequent share issuances from RSU vesting and warrant exercises add to the float.
Key Events · Earnings and Guidance · HELP
-
Q1 FY2027 Net Loss of $47.8M
Net loss nearly doubled from $24.6M a year ago, driven by a $30.8M research spend as the Phase 3 APPROACH trial neared completion.
-
Cash Position of $166.4M
Cash at June 30, 2026 was $166.4M, with operating cash outflow of $37.1M for the quarter — implying roughly 4-5 quarters of runway at current burn.
-
Phase 3 APPROACH Data on Track for Q4 2026
Enrollment completed with 223 participants; topline efficacy data readout remains expected in Q4 2026.
-
Post-Quarter Share Issuances Expand Float
7,889,846 shares issued on RSU vesting July 1, 2026, and 2,997,248 shares issued on pre-funded warrant exercise August 10, 2026 — a combined ~15% increase to shares outstanding.
Analysis · HELP · Life Sciences
Helus Pharma's first-quarter fiscal 2027 results show a net loss of $47.8 million, nearly double the prior-year loss, driven by a surge in research spending as the company pushes its Phase 3 APPROACH trial toward a Q4 2026 data readout. Cash of $166.4 million provides runway, but the burn rate of $37.1 million per quarter means the company will likely need additional capital before commercialization. The filing also reveals significant share issuance after quarter-end — 7.9 million shares from RSU vesting and 3.0 million from pre-funded warrant exercises — which expands the float and could pressure the stock near its 52-week high.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.5% of the 1476 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HELP was trading at $11.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $3.76 to $11.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.